AbbVie (ABBV) announced that it has settled litigation with all generic manufacturers that filed abbreviated new drug applications with the Food and Drug Administration for generic versions of upadacitinib tablets, which AbbVie markets as Rinvoq. “Given the settlement and license agreements, which are subject to standard acceleration provisions, assuming pediatric exclusivity is granted, no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States,” the company said in a regulatory filing. Shares of AbbVie are up 4% to $220.77 following the news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Settles to Delay RINVOQ Generics Until 2037
- AstraZeneca and AbbVie: New Phase II Study Targets Relapsed CLL/SLL
- AbbVie’s ABBV-525 Study: A Potential Game-Changer in B-Cell Malignancies
- AbbVie’s Promising Phase 2 Study on ABBV-932 for Anxiety Disorder
- AbbVie’s Promising Study on ABBV-706 for Small Cell Lung Cancer